Marketing Authorisation Application submitted in EU for sublingual house dust mite (HDM) allergen immunotherapy tablet STAGR320

Application is based on phase III trial (n=1600) assessing treatment of HDM-induced allergic rhinitis in adult and adolescent patients with or without intermittent asthma, which is reported to have achieved both its primary efficacy endpoint and key secondary endpoints.


Biospace Inc.